Breaking News


Circulating regulatory T cells upregulated by biological therapies and correlate with clinical response in psoriasis


A study in 30 consecutive patients with psoriasis vulgaris/arthropathic psoriasis treated with biologicals (infliximab, efalizumab and etanercept) analyzed circulating CD4+C25 bright FOXP3+ subset T cells with respect to clinical response. Clinical response outcomes were determined with the Psoriasis Area and Severity Index (PASI) and the American College of Rheumatology (ACR) criteria. An improvement of 75% of more of the baseline scores was determined, the PASI 75 and ACR 75 constituted a "response". A response was obtained in 91.1% of patients with an increase in CD25brightFOXP3+ values and in 27.3% of those who experienced a decrease during treatment (P = 0.0001). Responders showed significantly higher values versus nonresponders from the first 2 months ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list